What's new? Log in Free sign up

Filing search / Nkarta, Inc. / "Intensity"

Search information

Nkarta, Inc.

Companies

"Intensity"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

3 results

Newest first Best match first

NKTX Nkarta, Inc.

Regulation FD Disclosure

s347. 4 of 4 CR in retreatment of patients with progression after NKX019 Study amended to increase dose intensity and prevent relapse 7 of 10 CR

NKTX Nkarta, Inc.

Regulation FD Disclosure

in retreatment of patients with progression after NKX019 Study amended to increase dose intensity and prevent relapse 7 of 10 CR in Phase 1 dose escalation

NKTX Nkarta, Inc.

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

and ULBP 1/3 H-score combines % positive cells and intensity of expression Ligand expression trends higher among responders at higher doses (≥1B) NKG2D

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.